Amgen Inc. (AMGN)
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.
Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing
Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.
Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock.
Trade Tracker: Kevin Simpson buys Howmet, buys more Amgen
Kevin Simpson, Capital Wealth Planning founder and CIO, joins CNBC's "Halftime Report" to detail his latest portfolio buys.
2 Surefire Dividend Stocks That Could Pay You for Life
Dividend investing is an excellent strategy for (at least) two reasons. Companies that can provide consistent payouts generally have robust underlying operations.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Trade Tracker: Karen Firestone buys Amgen and buys more HealthEquity
Karen Firestone, executive chairman at Aureus Asset Management, joins CNBC's "Halftime Report" to detail her latest stock purchases. The Investment Committee debate healthcare and biotech companies.
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Amgen (AMGN) closed at $314.38, marking a -0.53% move from the previous day.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why the Market Dipped But Amgen (AMGN) Gained Today
Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.
